Business
NurExone Announces Appointment of New Director and Provides Corporate Updates
Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - July 7, 2023) - NurExone Biologic Inc. (...
About this update from Nurexone Biologic Inc
[{"type":"text","content":"NurExone Announces Appointment of New Director and Provides Corporate UpdatesToronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - July 7, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (\"NurExone\" or the \"Company\") is pleased to announce that, effective July 6, 2023, Dr. Gadi Riesenfeld has been appointed to the board of directors of the Company replacing Mr. Ron Mayron, who resigned for personal reasons.Dr. Riesenfeld has served on the board of directors and as president of several bio-pharmaceutical companies, including Kamapharm Ltd., Galisar Ltd., and OticPharma. Moreover, he was previously the president of Pharmos Corporation, a publicly traded biotech company listed on NASDAQ. Dr. Riesenfeld holds a Ph.D. degree from the Faculty of Agriculture of the Hebrew University of Jerusalem and held a scientific position, as a post doctorate, at the Cedars Sinai Medical Center in Los Angeles, California. The Company is excited to have Dr. Riesenfeld on its board of directors and believes his rich corporate experience as well as his knowledge of the pharmaceutical industry will benefit the board and the Company. NurExone thanks Mr. Mayron for his service on the board of directors of the Company.Corporate UpdatesOn June 28, 2023, the Company held its annual and special meeting of shareholders (the \"Meeting\"). At the Meeting, shareholders approved all proposed resolutions as set out in the management information circular dated May 23, 2023 (the \"Circular\"), available at the Company's SEDAR profile on www.sedar.com, including the adoption of the Company's omnibus equity incentive plan, as amended (the \"Plan\"). The text of the Plan as well as a summary of the Plan is contained in the Circular. The maximum number of common shares issuable pursuant to awards granted under the Plan is 7,713,928 common shares, being a fixed amount equal to 18% of the issued and outstanding common shares of the Company as of the date of the Meeting.The Company also announces that it will make an application to the TSX Venture Exchange to amend the exercise price of 13,815,730 outstanding common share purchase warrants of the Company (the \"Warrants\"). The Warrants currently have an exercise price of CAD$1.20 per common share and expire on June 15, 2024. The Warrants will be amended to adjust their exercise price to CAD$0.38 per c...